Sonelokimab - MoonLake Immunotherapeutics
Alternative Names: ALX 0761; Anti-IL-17A/F Nanobody; M 1095; MSB-0010841; Nanobody® IL-17 A/F inhibitor; SonelokinabLatest Information Update: 13 Aug 2024
At a glance
- Originator Ablynx
- Developer Avillion; MoonLake Immunotherapeutics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Single-domain antibodies; Skin disorder therapies
- Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hidradenitis suppurativa
- Phase II Psoriasis; Psoriatic arthritis
- No development reported Ankylosing spondylitis
Most Recent Events
- 07 Aug 2024 MoonLake Immunotherapeutics plans phase III VELA TEEN trial in Hidradenitis suppurativa (In adolescents) in 2024 (SC)
- 07 Aug 2024 MoonLake Immunotherapeutics plans two phase II trials in Dermatology and Rheumatology indications in end of 2024
- 28 Jun 2024 No recent reports of development identified for phase-I development in Ankylosing-spondylitis in Switzerland (Parenteral)